Last reviewed 2026-05-14 · How we verify

2032 Pharmaceutical Patent Cliff

61 marketed drugs with patents expiring in 2032, joined to sponsor + therapeutic area + drug class. Forward-looking forecast. Sourced from FDA Orange Book + USPTO Patent Public Search.

Sponsors most affected (10)

1. Pfizer · 8 drugs
2. Merck & Co. · 4 drugs
3. AbbVie · 3 drugs
4. Unknown · 2 drugs
5. Pfizer Inc. · 2 drugs
6. Novartis · 2 drugs
7. Bayer · 1 drug
8. Purdue Pharma Lp · 1 drug
9. Novo Nordisk · 1 drug
10. Exelixis · 1 drug

By therapeutic area

Oncology (22)

• 2032-01-19 — Mavyret · AbbVie · Hepatitis C Virus NS5A Inhibitor [EPC]
• 2032-01-29 — Venclexta · AbbVie · BCL-2 Inhibitor [EPC]
• 2032-02-08 — Elocon · Merck & Co. · Corticosteroid · Formulation
• 2032-02-10 — Cometriq · Exelixis · Kinase Inhibitor
• 2032-03-04 — Taxol · Pfizer · Microtubule Inhibitor
• 2032-03-04 — Taxol · Pfizer · Microtubule Inhibitor [EPC] · Method of Use
• 2032-04-13 — Viekira Pak (Copackaged) · AbbVie · Hepatitis C Virus Non-Nucleoside NS5B Palm Polymerase Inhibitor
• 2032-04-15 — Gemzar · Accord Hlthcare · Nucleoside metabolic inhibitor · Formulation
• 2032-04-16 — Sandimmune · Novartis · Calcineurin Inhibitor Immunosuppressant [EPC]
• 2032-04-25 — Pepaxto · Oncopeptides Ab · Alkylating Drug
• 2032-05-10 — Torisel · Pfizer · temsirolimus
• 2032-05-11 — Decadron · Generic (originally Merck) · Corticosteroid [EPC] · Formulation
• 2032-05-11 — Decadron-La · Merck & Co. · Corticosteroid · Formulation
• 2032-05-23 — Akynzeo · Helsinn Hlthcare · Serotonin-3 Receptor Antagonist [EPC]
• 2032-07-25 — Tagrisso · AstraZeneca · Kinase Inhibitor [EPC]
• 2032-08-23 — Detectnet · Radiomedix · Radioactive Diagnostic Agent [EPC]
• 2032-11-03 — Velcade · Shilpa · Proteasome inhibitor · Formulation
• 2032-11-19 — Cortef · Generic (originally Merck/Upjohn) · Corticosteroid [EPC] · Method of Use
• 2032-11-19 — Solu-Cortef · Pfizer · Corticosteroid · Method of Use
• 2032-11-19 — Cortifoam · Pfizer · Corticosteroid · Method of Use
• 2032-11-21 — Estrace · Pfizer · Estrogen · Method of Use
• 2032-11-21 — Estring · Pfizer Inc. · Combined Oral Contraceptive (COC) · Method of Use

Metabolic (14)

• 2032-01-01 — Beconase Aq · Corticosteroid
• 2032-02-01 — Ozempic · Novo Nordisk · GLP-1 Receptor Agonist [EPC]
• 2032-03-07 — Tradjenta · Boehringer Ingelheim · Dipeptidyl Peptidase 4 Inhibitor [EPC]
• 2032-03-11 — NITROGLYCERIN · Nitrate Vasodilator [EPC] · Formulation
• 2032-03-11 — Nitroglycerin · Fougera · Nitrate Vasodilator [EPC]
• 2032-04-06 — Acetadote · Bristol-Myers Squibb · Antidote · Method of Use
• 2032-06-13 — Valium · Generic (originally Roche) · Benzodiazepine [EPC] · Method of Use
• 2032-06-28 — Amphetamine Sulfate · UCB · Central Nervous System Stimulant
• 2032-07-27 — Azstarys · Commcave Therapeutics Sa
• 2032-09-01 — Cuvposa · Shionogi · Anticholinergic
• 2032-09-01 — Glycopyrrolate · Yonsei University · Formulation
• 2032-09-07 — Zosyn · Merck Sharp & Dohme B.V. · beta Lactamase Inhibitor
• 2032-11-21 — Femring · Apil · Estrogen · Method of Use
• 2032-12-12 — Ongentys · Neurocrine Biosciences · Catechol-O-Methyltransferase Inhibitor [EPC]

Immunology (9)

• 2032-01-03 — Tussionex Pennkinetic · Bayer · Histamine-1 Receptor Antagonist
• 2032-03-11 — Acetaminophen · Polymedica · acetaminophen
• 2032-03-16 — Advil · Generic (originally Boots Group) · Nonsteroidal Anti-inflammatory Drug [EPC] · Method of Use
• 2032-04-16 — Sandimmune · Novartis AG (originally Sandoz) · Calcineurin inhibitor (immunosuppressant) · Formulation
• 2032-05-11 — Dexamethasone Sodium Phosphate · Merck & Co. · Corticosteroid · Formulation
• 2032-06-28 — Metro I.V. In Plastic Container · Baxter · Nitroimidazole Antimicrobial [EPC] · Method of Use
• 2032-08-14 — Cupric Sulfate · Abraxis Pharm · copper sulfate · Formulation
• 2032-08-15 — Biktarvy · Gilead Sciences · Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]
• 2032-09-29 — Norgesic · Endo · centrally acting muscle relaxant with anticholinergic properties

Neuroscience (6)

• 2032-01-06 — Subutex · Purdue Pharma Lp · Partial Opioid Agonist · Formulation
• 2032-02-13 — Lybalvi · Alkermes Inc · Atypical Antipsychotic [EPC]
• 2032-04-10 — Risperdal · Johnson & Johnson (Janssen) · Atypical Antipsychotic [EPC] · Formulation
• 2032-06-13 — Abilify · Generic (originally Otsuka/BMS) · Third-generation antipsychotic (D2 partial agonist) · Formulation
• 2032-06-28 — Ritalin · Novartis · Formulation
• 2032-11-16 — Inbrija · Merz · Aromatic Amino Acid [EPC] · Formulation

Pain (3)

• 2032-02-04 — Naloxone Hydrochloride · Pfizer Inc. · Mixed opioid agonist-antagonist with opioid antagonist · Formulation
• 2032-08-14 — Arnicare Leg Cramps · Sebela Womens Hlth · Copper-containing Intrauterine Device [EPC] · Formulation
• 2032-12-21 — Subutex · Indivior · partial opioid agonist · Method of Use

Cardiovascular (2)

• 2032-01-01 — Proventil · Merck & Co. · beta2-Adrenergic Agonist
• 2032-01-04 — Dexmedetomidine Hydrochloride · Pfizer · dexmedetomidine

Infectious Disease (2)

• 2032-06-15 — Avycaz · Cerexa Inc · beta Lactamase Inhibitor [EPC]
• 2032-09-07 — Zerbaxa · Cubist Pharms · Cephalosporin Antibacterial

Ophthalmology (1)

• 2032-03-09 — Miralax · Braintree · Osmotic Laxative [EPC]

Other (1)

• 2032-03-09 — Sodium Chloride · Pfizer · sodium chloride

Hematology (1)

• 2032-10-26 — Livmarli · Mirum Pharma Inc · Ileal Bile Acid Transporter Inhibitor

Subscribe to patent-cliff alerts

Push every new patent expiry into your RSS reader:

• Marketed-drug events RSS
• All 2032 pharma events (approvals + readouts + patents)

Related

• Biosimilar tracker — who's competing for each post-cliff originator
• Patent cliff revenue calculator
• 2032 patent expiries dataset (CSV / JSON)